Advertisement
NYU Trial: Psilocybin + Buprenorphine for Opioid Use Disorder
From NYU Langone Psychiatry on YouTube
·
44:18
·
Clinical Trials
About This Video
Principal investigator presentation on the NYU Phase 2 trial examining psilocybin-assisted therapy as an adjunct to buprenorphine maintenance for opioid use disorder. Covers trial design, rationale, safety monitoring, and preliminary signals.
Key Takeaways
- This trial examines psilocybin as adjunctive to buprenorphine, not a replacement for medication-assisted treatment.
- The mechanistic hypothesis: psilocybin addresses psychological dimensions of addiction that pharmacotherapy doesn't reach.
- Primary endpoints: retention in treatment and illicit opioid use at 3 months.
- Ibogaine has more data for opioid detox but serious cardiovascular risks; psilocybin's profile is safer but works differently.
Advertisement